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Rat insulin II, unlike rat insulin I and other non-rodent insulins, contains a unique methionine residue at position B29. 
Reversed-phase HPLC allows for separation of the two rat insulins, with insulin I typically eluting faster than insulin 
II. An anomalous peak of insulin immunoreactive material was found eluting even faster than insulin I following acid 
extraction of rat insulin-producing cells. This early peak co-eluted with [Met-OB29]insulin II suggesting that during cell 
extraction and subsequent purification steps, rat insulin II is subject o selective oxidation at Met s29. Such oxidation of 
rat proinsulin II affords improved separation from rat proinsulin I compared to the native form. 
Insulin biosynthesis; HPLC; Methionine sulfoxide; (Rat) 
1. INTRODUCTION 
Reversed-phase HPLC is the method of choice 
for the analysis of insulin and related peptides and 
has allowed for identification of mutant human in- 
sulins [1] and for the separation of proinsulin and 
its conversion intermediates [2]. This analytical 
method has allowed for separation of the protein 
products of the two non-allelic rat insulin genes, rat 
insulins I and II [3-6] and rat C-peptides I and II 
[7]. The separation of rat proinsulin I and II by 
HPLC proved not to be as successful [3,6]. 
We have recently succeeded in transfecting cells 
of a corticotroph line (AtT20 cells) with the rat in- 
sulin II gene [8]. These cells were found to produce 
and secrete immunoreactive insulin. When the cells 
were extracted and insulin immunoreactive prod- 
ucts analysed by HPLC, we detected not only pro- 
insulin II and insulin II but also a third prominent 
peak of immunoreactive material eluting rapidly 
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from the HPLC system. Although initially thought 
to be a proinsulin conversion intermediate [8] 
(possibly mono- or diarginyl insulin), it became ap- 
parent that the kinetics of the production of this 
material, and its abundance relative to that of pro- 
insulin and insulin, were not consistent with this 
assignment. The present study provides evidence 
that this material is the sulfoxide form of rat in- 
sulin II ([Met-OB29]insulin II), suggesting that the 
extraction and pre-purification techniques used by 
us and others prior to HPLC analysis of insulin 
related peptides, favour selective oxidation of 
Met a29 of rat insulin II. Taking this observation i - 
to account, the interpretation f the HPLC profiles 
becomes straightforward, and, furthermore, the 
oxidation of rat proinsulin II allows for its separa- 
tion from rat proinsulin I much more readily than 
for the native form. 
2. MATERIALS AND METHODS 
2.1. Biosynthetic labelling of rat proinsulins and insulins 
Islets of Langerhans were isolated from the pancreas of adult 
male Sprague-Dawley rats by a modification of the collagenase 
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digestion method [9] and islets separated from exocrine tissue by 
the use of Histopaque 1083 (Sigma, St Louis, MO, USA). After 
24 h in tissue culture (DMEM, 10% newborn calf serum, 8.3 
mM glucose) the islets were labelled for 1 h at 37°C in Krebs 
Ringer bicarbonate buffer containing 10 mM Hepes, 0.1% 
(w/v) bovine serum albumin, 16.7 mM glucose and either 1 
mCi/ml [~H]leucine or [35S]methionine (both from Amersham 
International, Amersham, Bucks, England). After washing 
twice in the above buffer without labelled amino acids and con- 
taining 2.8 mM glucose, the islets were incubated for up to 2 h 
in the wash buffer to allow for conversion of radioactively 
labelled proinsulin to insulin. Labelled products were extracted 
from the islets by sonication on ice in 0.2 M glycine/0.1% BSA, 
pH 8.8. Extracts from islets harvested at selected times of the 
chase incubation following labelling with either [~H]leucine or 
[3-~S]methionine w re mixed together in order to obtain a solu- 
tion with radioactivity distributed in roughly equal amounts be- 
tween [3H]insulin I; [3H]proinsulin I; [3H]proinsulin I1; lass]in- 
sulin lI; [35S]proinsulin II.
2.2. Extraction of transfected AtT20 cells and pre-purification 
of proinsulin/insulin 
ART20 cells were transfected with the rat insulin lI gene as 
described previously ([8] and manuscript inpreparation). Stable 
transfectants (based upon ability to grow in the presence of the 
antibiotic G418) were screened for insulin immunoreactivity and 
positive clones then expanded in tissue culture. After washing in 
PBS, cells were extracted in 5 M acetic acid, 0.1% BSA. The 
acid extracts were freeze-thawed thrice and then sonicated. In- 
sulin and proinsulin were then concentrated by adsorption and 
selective lution from a C18 Sep-Pak cartridge (Waters Asso- 
ciates, Milford, MA, USA) [10]. The eluted products were 
lyophilised and then dissolved in 0.5% trifluoroacetic acid, 
2.3. Reversed phase HPLC 
A Beckman System Gold consisting of a model 126 program- 
mable solvent module and a model 166 programmable d tector 
module was used with a Beckman Ultrasphere ODS 5/~m col- 
umn (4.6× 250 mm). The two buffer systems used were: (A) 
TEAP (50 mM phosphoric acid, 20 mM triethylamine, 50 mM 
sodium perchlorate, adjusted to pH 3.0 with NaOH); (B) 90% 
acetonitrile, 10% water (v/v). Insulin and related peptides were 
eluted using a modification of our previous methods [3,4]. This 
modification allowed for better separation of rat proinsulin I 
from II, particularly following oxidation of proinsulin lI. The 
two rat insulins were eluted isocratically at 34.5% B. At 25 rain 
the composition of the elution mixture was changed to 37% B 
over a 60 min period using a convex curve for increasing the B 
component ('curve 3' of the Beckman System Gold). The curve 
is depicted in fig.2. 
2.4. Selective oxidation of MetB 29 of rat insulin H 
Aliquots of the mixture containing the radioactively abelled 
rat insulins and proinsulins were acidified to pH 2.5 using 1 M 
perchloric acid and a solution of 35% hydrogen peroxide was 
then added to obtain a final concentration f 1%, or approx. 0.3 
M, in peroxide. Oxidation was allowed to proceed for 1 h at 
room temperature. This protocol was adapted from a published 
procedure for the selective oxidation of methionine residues in 
protein [11]. The oxidised sample was then lyophilised and 
redissolved in 0.1% trifluoroacetic acid, 0.1% BSA before in- 
jection into the HPLC system. Controls were handled in parallel 
with the exception of the omission of peroxide. 
2.5. Insulin radioimmunoassay 
Insulin immunoreactivity was measured by radioim- 
munoassay using the charcoal-dextran separation technique 
[12]. Rat insulin was used as the standard (Novo Industri, 
Bagsvaerd, Denmark) with guinea-pig anti-insulin serum. 
3. RESULTS AND DISCUSSION 
AtT20 cells t rans fected  w i th  the rat  insu l in  II 
gene were ext rac ted  in ac id and  the ext racted  
products  f irst p re -pur i f ied  and  concent ra ted  us ing 
a C18 Sep-Pak .  Mater ia l  e lut ing f rom the Sep-Pak  
was lyophi l i sed,  red isso lved and  then  app l ied  to 
HPLC.  The  f rac t ions  e lut ing f rom the HPLC 
system were lyoph i l i sed  and  reconst i tu ted  be fore  
be ing  assayed for  insu l in  immunoreact iv i ty .  The  
e lu t ion  pro f i le  for  insu l in  immunoreact iv i ty  is 
shown in f ig . lA .  The  f i rst  peak  e luted at approx .  
11-13 min  re fer red  to be low as 'ear ly  peak '  and  the 
second at 23-26  min .  An  e lu t ion  prof i le  for  an  ex- 
t rac t  o f  rat  islets is shown be low,  in f ig . lB .  Aga in  
two  peaks  are observed ,  but  they  cor respond to 
nat ive  rat  insu l ins  I and  II as ind icated .  As  can  be 
seen,  the  second of  the  two peaks  f rom the t rans -  
fected cells co -e luted wi th  rat  insu l in  I I .  There  was, 
however ,  no  immunoreact iv i ty  for  islet ext racts  
e lu t ing  at 11-13 rain.  It shou ld  be noted  that  the 
islets were ext rac ted  and  then  immediate ly  ana lysed  
by  HPLC w i thout  the in terven ing  concent ra t ion  
step us ing  the Sep-Pak  car t r idge.  I f  islets were 
hand led  in para l le l  w i th  t rans fected  cells and  pro-  
cessed ident ica l ly ,  then  immunoreact ive  mater ia l  
e lu t ing  at 11-13 min  was generated  at the  expense 
o f  immunoreact iv i ty  assoc iated  wi th  rat  insu l in  II 
(not  shown) .  In terest ing ly ,  this  was not  a repro -  
duc ib le  f ind ing  and ,  fu r thermore ,  the  re lat ive 
amount  o f  ear ly  peak  mater ia l  and  nat ive  insu l in  II 
was found to vary  cons iderab ly  f rom one  exper i -  
ment  to the next ,  both  for  t rans fected  cells and  
nat ive  islets. 
Taken  together ,  these observat ions  uggested to 
us that  we were dea l ing  wi th  some change to rat  in- 
su l in  II a r i s ing dur ing  the  ext rac t ion /pur i f i ca t ion  
procedure  rout ine ly  used for  the  t rans fected  cells. 
S ince,  in nat ive  islets, on ly  insu l in  II seemed to 
generate  ear ly  peak  mater ia l ,  our  a t tent ion  was 
drawn to Met  B29, a res idue un ique  to rat  (and  
mouse)  insu l in  II. In par t i cu la r ,  we specu la ted  that  
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Fig.l .  Insulin immunoreactivity in fractions eluting from 
reversed-phase HPLC under isocratic onditions (34.5%, buffer 
B). (A) Material extracted from AtT20 cells transfected with the 
gene for rat insulin II. (B) Material extracted from rat islets. (C) 
Material extracted from rat islets and oxidised (incubated under 
acidic conditions with peroxide) before analysis by HPLC.  The 
elution times for rat insulins I and II are as indicated. 
this residue may be sensitive to oxidation and 
especially so under acidic conditions [11,13,14]. 
We therefore incubated islet extracts under acidio 
conditions with peroxide using conditions mild 
enough not to oxidise any residues other than 
methionine [11,14]. HPLC analysis of this material 
is shown in fig. 1C. The peroxide oxidation resulted 
in a complete disappearance of rat insulin II im- 
munoreactivity in favour of an immunoreactive 
product eluting at 11-13 min. Rat insulin I was not 
affected by the peroxide treatment. The results 
strongly suggest that the early peak material found 
in the transfected cells and islets following acid ex- 
traction and prepurification by Sep-Pak is, thus, 
[Met-OB29]insulin II. 
The production of the sulfoxide form of insulin 
II during certain extraction procedures can clearly 
lead to confusing HPLC elution profiles. Indeed, 
we ourselves initially suspected that the early peak 
material in the transfected cells was a proinsulin 
conversion intermediate [8]. A review of the litera- 
ture indicates that the problem is not unique to rat 
insulin II and extraction of insulin-producing cells. 
Thus, acid extraction of a peptide with corcito- 
tropin-releasing activity from ovine hypothalamus 
led to purification of a peptide which eluted from 
HPLC some 5 rain earlier than the chemically syn- 
thesized peptide standard and which displayed 
reduced biological activity [13]. Based upon the 
same series of experiments as described here, the 
authors concluded that during their extraction pro- 
cedures, they were generating the methionine 
sulfoxide form of the peptide. 
Despite the ease of separation of rat C-peptides 
I and II, and rat insulins I and II by HPLC [3-6], 
the separation of the two rat proinsulins has not 
proved as simple [3,6]. Based upon the dramatic 
change in mobility of rat insulin II following oxida- 
tion of Met B29, we speculated that [Met-OB29]pro - 
insulin II may prove readily separable from both 
native proinsulin II and, more importantly, from 
rat proinsulin I. As shown in fig.2, our present con- 
vex gradient system allows for a modest separation 
of the two proinsulins, but they cannot be clearly 
resolved. The mixture of labelled insulin I and II, 
and proinsulins I and II was then oxidised as 
described earlier for islet extracts. Insulin II (la- 
belled with [35S]methionine) now eluted at 11-13 
min as expected for the sulfoxide form. Native rat 
proinsulin II eluted at 67-69 rain, whereas after its 
oxidation [Met-OB29]proinsulin II eluted at 51-54 
min, allowing for clear separation from rat proin- 
sulin I, the elution time of which was unaffected by 
peroxide treatment. 
In conclusion, under certain circumstances, the 
acid extraction of rat insulin-producing cells can 
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Fig.2. Effect of oxidation upon elution times of rat insulin II 
and proinsulin II by reversed-phase HPLC. Aliquots of a 
solution containing [3H]rat insulin I, [3H]rat proinsulin I, 
[3H]rat proinsulin lI, [35S]rat insulin II and [35S]rat proinsulin 
II, were loaded onto the HPLC system either before (control) or 
after (oxidised) oxidations(see l gend to fig.l). The HPLC 
elution conditions were as follows (buffer B = 90070 acetonitrile; 
10% H20): 34.5% B for the first 25 min; increased from 34.5 to 
37% B from 25 to 65 min using a convex curve as indicated in 
the upper panel of the figure. The identity of the numbered 
peaks is: (1) rat insulin l; (2) rat insulin II; (3) rat proinsulin I; 
(4) rat proinsulin II; (5) rat [Met-O B29] insulin II; (6) rat [Met- 
O B29] proinsulin I1. 
lead to selective oxidation of rat insulin II Met Bz9. 
Understanding this allows for unambiguous inter- 
pretation of HPLC elution profiles during analysis 
of such material. Advantage can be taken of the 
pronounced change in elution times of rat proin- 
sulin II vs rat [Met-O 829] proinsulin II in order to 
separate rat proinsulin I from II by HPLC.  
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